Point-of-Care Glucose Testing

Global Point-of-Care Glucose Testing Market to Reach US$4.1 Billion by 2030

The global market for Point-of-Care Glucose Testing estimated at US$3.4 Billion in the year 2024, is expected to reach US$4.1 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Accu Check Aviva Meter, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Onetouch Verio Flex segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$916.5 Million While China is Forecast to Grow at 6.4% CAGR

The Point-of-Care Glucose Testing market in the U.S. is estimated at US$916.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$819.4 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Point-of-Care Glucose Testing Market – Key Trends & Drivers Summarized

Why Is Point-of-Care Glucose Testing Essential in Diabetes Management?

Point-of-care (PoC) glucose testing plays a crucial role in diabetes management, emergency care, and critical care settings, providing immediate blood glucose readings that enable healthcare providers and patients to make real-time treatment decisions. Unlike traditional laboratory-based glucose tests, which require sample processing time, PoC glucose meters allow for rapid, on-the-spot glucose monitoring in hospitals, clinics, ambulatory settings, and even home environments.

The global rise in diabetes prevalence is one of the major factors driving the adoption of PoC glucose testing. According to the International Diabetes Federation (IDF), over 537 million adults worldwide have diabetes, and this number is expected to grow significantly in the coming years. Effective glucose monitoring and glycemic control are critical in preventing complications such as hypoglycemia, ketoacidosis, and cardiovascular diseases, making PoC glucose testing an integral part of routine diabetes care.

The increasing adoption of self-monitoring blood glucose (SMBG) devices and continuous glucose monitoring (CGM) systems has empowered diabetic patients to track their glucose levels frequently and make lifestyle or medication adjustments accordingly. Additionally, hospitals and emergency departments rely on PoC glucose meters for rapid hypoglycemia and hyperglycemia detection, ensuring immediate therapeutic interventions and improved patient outcomes.

How Are Technological Advancements Improving PoC Glucose Testing?

The PoC glucose testing market is rapidly evolving with advancements in biosensor technology, connectivity solutions, and non-invasive glucose monitoring techniques.

One of the most significant innovations is the integration of wireless connectivity and digital health solutions. Modern PoC glucose meters are now equipped with Bluetooth, Wi-Fi, and mobile app compatibility, allowing seamless data transmission to electronic health records (EHRs), cloud-based platforms, and diabetes management applications. This feature enables remote patient monitoring (RPM) and physician-patient collaboration, making diabetes management more proactive and efficient.

Another breakthrough is the development of non-invasive and minimally invasive glucose monitoring devices. Traditional blood glucose testing requires finger-pricking, which can be painful and inconvenient for patients. Companies are now focusing on needle-free glucose monitoring using wearable biosensors, sweat-based glucose detection, and optical glucose sensors that utilize infrared light to measure glucose levels through the skin. Non-invasive glucose testing is expected to revolutionize diabetes management by enhancing patient adherence and improving user experience.

Advancements in continuous glucose monitoring (CGM) systems are also reshaping the market. Unlike traditional PoC glucose meters that provide single-time readings, CGMs offer real-time glucose monitoring with trend analysis and alerts for hypoglycemia or hyperglycemia. Leading manufacturers, such as Abbott (FreeStyle Libre), Dexcom (G6 and G7), and Medtronic (Guardian Connect), are continuously improving CGM technology to offer longer sensor wear, improved accuracy, and integration with insulin pumps.

Additionally, AI-driven glucose analytics and predictive algorithms are enhancing the precision of glucose monitoring. Machine learning models can now analyze glucose trends, predict fluctuations, and provide personalized recommendations for insulin dosing, meal planning, and physical activity adjustments. AI-powered PoC glucose testing solutions are expected to reduce complications, improve glycemic control, and support personalized diabetes management.

Why Is Demand for PoC Glucose Testing Growing Across Healthcare and Homecare Settings?

The increasing prevalence of diabetes, metabolic disorders, and lifestyle-related diseases has led to the widespread adoption of PoC glucose testing in hospitals, outpatient clinics, and homecare settings.

• Hospital & Critical Care Use: Healthcare facilities utilize PoC glucose testing for rapid diagnosis and management of acute glycemic events in intensive care units (ICUs), emergency rooms (ERs), and perioperative care. Patients undergoing surgery, trauma care, or chemotherapy often experience fluctuations in blood glucose levels, necessitating frequent bedside glucose monitoring to prevent complications.
• Self-Monitoring & Homecare: The demand for self-monitoring blood glucose (SMBG) devices has surged as more individuals manage diabetes independently at home. Compact, user-friendly glucose meters with easy-to-read displays, voice-assisted functions, and cloud-based tracking have made home-based glucose monitoring more convenient, particularly for elderly and visually impaired patients.
• Gestational Diabetes Monitoring: Pregnant women diagnosed with gestational diabetes mellitus (GDM) require frequent glucose monitoring to prevent complications for both the mother and baby. The adoption of portable, disposable, and wireless glucose meters in prenatal care is increasing to support early detection and management of GDM.
• Sports & Fitness Applications: Athletes and fitness enthusiasts are using PoC glucose testing and CGMs to monitor glucose variations before and after workouts. This trend has fueled demand for wearable glucose monitors that provide real-time insights into metabolic health and energy optimization.

The expansion of telemedicine and digital health platforms has also contributed to the growing demand for PoC glucose testing solutions. Many telehealth providers now integrate glucose monitoring data with virtual consultations, enabling remote diabetes management and early intervention for high-risk patients.

What Factors Are Driving the Growth of the PoC Glucose Testing Market?

The growth in the PoC glucose testing market is driven by technological advancements, increasing diabetes prevalence, and rising consumer awareness about proactive healthcare.

• Rising Diabetes Prevalence & Chronic Disease Burden: The global diabetes epidemic continues to fuel demand for real-time glucose monitoring solutions. Developing countries, particularly in Asia-Pacific, Latin America, and Africa, are experiencing a surge in diabetes cases, prompting governments to implement nationwide diabetes screening and prevention programs that incorporate PoC glucose testing.
• Government & Insurance Support for Diabetes Management: Many countries are expanding insurance coverage and reimbursement policies for glucose monitoring devices, making PoC glucose meters and CGMs more accessible to diabetic patients. Health agencies such as the FDA, EMA, and WHO are promoting the use of connected glucose meters and AI-driven diabetes management tools to improve healthcare outcomes.
• Increased Adoption of Wearable & Smart Glucose Monitoring Devices: The transition from traditional glucose meters to smart CGMs and biosensors is reshaping diabetes care. The demand for wearable CGMs with automated insulin delivery integration is growing, particularly among Type 1 and insulin-dependent Type 2 diabetic patients.
• Growing Demand for Minimally Invasive & Painless Testing Methods: Non-invasive glucose monitoring solutions are expected to gain traction as patients seek less painful, convenient, and continuous glucose tracking options. Research into tear, sweat, and saliva-based glucose detection is gaining momentum, with companies investing in next-generation non-invasive glucose sensors.
• Rise of AI & Data Analytics in Diabetes Care: AI-driven predictive analytics, glucose trend forecasting, and personalized diabetes coaching are transforming how patients and healthcare providers manage blood sugar levels. The integration of machine learning algorithms into PoC glucose testing devices is expected to optimize treatment decisions and reduce diabetes-related complications.

With continuous innovations in glucose monitoring technology, increasing adoption of remote patient monitoring, and expanding applications in healthcare and home settings, the PoC glucose testing market is set for exponential growth. As connected health solutions, AI-driven diagnostics, and patient-centered diabetes management strategies evolve, PoC glucose testing will remain a cornerstone of personalized, data-driven healthcare worldwide.

SCOPE OF STUDY:

The report analyzes the Point-of-Care Glucose Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Accu Check Aviva Meter, Onetouch Verio Flex, i-STAT, Bayer Contour Blood Glucose Monitoring System, Freestyle Lite, True Metrix, Accu-Chek Inform II, StatStrip, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• ACON Laboratories, Inc.
• ARKRAY, Inc.
• Ascensia Diabetes Care Holdings AG
• Bayer AG
• Dexcom Inc.
• EKF Diagnostics Holdings plc
• F. Hoffmann-La Roche Ltd.
• iHealth Labs Inc.
• Insulet Corporation
• LifeScan Inc.
• Medtronic plc
• Nipro Corporation
• Nova Biomedical
• Prodigy Diabetes Care, LLC
• PTS Diagnostics
• Sanofi S.A.
• Terumo Corporation
• Trividia Health, Inc.
• Ypsomed Holding AG

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.